JP5845178B2 - ワクチン生産のためのポリオウイルスの高力価での生産 - Google Patents
ワクチン生産のためのポリオウイルスの高力価での生産 Download PDFInfo
- Publication number
- JP5845178B2 JP5845178B2 JP2012519981A JP2012519981A JP5845178B2 JP 5845178 B2 JP5845178 B2 JP 5845178B2 JP 2012519981 A JP2012519981 A JP 2012519981A JP 2012519981 A JP2012519981 A JP 2012519981A JP 5845178 B2 JP5845178 B2 JP 5845178B2
- Authority
- JP
- Japan
- Prior art keywords
- poliovirus
- cells
- production
- cell
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000991587 Enterovirus C Species 0.000 title claims description 168
- 238000004519 manufacturing process Methods 0.000 title claims description 76
- 229960005486 vaccine Drugs 0.000 title description 48
- 238000000034 method Methods 0.000 claims description 80
- 208000015181 infectious disease Diseases 0.000 claims description 49
- 241000700605 Viruses Species 0.000 claims description 39
- 229960001539 poliomyelitis vaccine Drugs 0.000 claims description 17
- 241000274177 Juniperus sabina Species 0.000 claims description 11
- 241000709701 Human poliovirus 1 Species 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 230000002238 attenuated effect Effects 0.000 claims description 8
- 238000004114 suspension culture Methods 0.000 claims description 6
- 241000709704 Human poliovirus 2 Species 0.000 claims description 4
- 241000709727 Human poliovirus 3 Species 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 204
- 230000008569 process Effects 0.000 description 42
- 210000003501 vero cell Anatomy 0.000 description 33
- 238000004113 cell culture Methods 0.000 description 20
- 230000010412 perfusion Effects 0.000 description 20
- 229940029583 inactivated polio vaccine Drugs 0.000 description 18
- 239000000725 suspension Substances 0.000 description 17
- 208000000474 Poliomyelitis Diseases 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 210000004102 animal cell Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960004279 formaldehyde Drugs 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 230000001464 adherent effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000008029 eradication Effects 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229940124867 Poliovirus vaccine Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 229960004854 viral vaccine Drugs 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940127241 oral polio vaccine Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100388690 Plasmodium falciparum (isolate K1 / Thailand) MEF-1 gene Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 230000001769 paralizing effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000009285 membrane fouling Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32651—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
ウイルスまたはその免疫原性部分を含み、どちらも滅菌液体溶液、液体懸濁物または凍結乾燥されたバージョン(異形)のいずれかでもあり、そして随意に安定剤または賦形剤を含む。
エンドポイント力価(log10)=Xo-d/2+d/n*ΣXi
式中、Xoはすべての接種(植菌)がまだ陽性である最も高い希釈物のlog10値であり、dは用いる希釈係数のlog10値であり、nは各々の希釈物での複製の数であり、そしてΣXiは希釈物Xoを含む陽性であるすべてのウェルの合計である
ものを使用して計算した。
例2:懸濁物におけるPER.C6細胞でのポリオウイルスの効率的な生産
例3:懸濁PER.C6細胞でのポリオウイルスの産出量はより一層高い細胞密度で増加する
例4:バイオリアクターにおけるPER.C6細胞でのポリオウイルスの生産
(1)
Barrett(バレット)PN、Mundt(ムント)W、Kistner(キストナー)O、Howard (ハワード)MK。2009年。Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines(ワクチン製造でのベロ細胞プラットホーム:細胞培養ベースのウイルスワクチンに向かう動き)。Expert Rev. Vaccines 8: 607-618PN。
(2)
Bevilacqua(ベビラックァ)JM、Young(ヤング)L、Chiu(チウ)SW、Sparkes(スパークス)JD、Kreeftenberg(クリーフテンバーグ)JG。1996年。Rat immunogenicity assay of inactivated poliovirus(不活性化ポリオウイルスのラット免疫原性アッセイ)。Dev. Biol. Stand. 86: 121-127。
(3)
Campbell(キャンベル)SA、Lin(リン)J、Dobrikova(ドブリコバ)EY、Gromeier(グロメイヤー)M。2005年。Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells(HEK293細胞での細胞型特異的ポリオウイルス繁殖の遺伝的決定因子)。J. Virol. 79: 6281-6290。
(4)
Card(カード)CJ、Smith(スミス)T、Hunsaker(ハンセーカー)B、Barnett(バーネット)B。2005年。Serum-free production of poliovirus: A comparative study using microcarriers, roller bottles and stationary cell culture(ポリオウイルスの無血清生産:マイクロキャリヤー、ローラーボトルおよび静置細胞培養を用いる比較研究)。In: F. Godia(ゴディア)およびM. Fussenegger(フッセネガー)(編集)、Animal Cell Technology meets Genomics, 761-765。
(5)
Doi(ドイ)Y、Abe(アベ)S、Yamamoto(ヤマモト)H、Horie(ホリエ)Hら。2001年。Progress with inactivated poliovirus vaccines derived from the Sabin strains(セービン株由来の不活性化ポリオウイルスワクチンでの進歩)。In: Brown(ブラウン)F (編集): Progress in Polio Eradication: Vaccine Strategies for the End Game. Dev. Biol. 105: 163-169。
(6)
Van Eikenhorst(ヴァン・アイケンホースト)G、Bakker(バッカー)WAM、Thomassen(トマセン)YE、van der Pol(ファン・デア・ポル)LA。2009年。Platform technology for viral vaccine production: comparison between attached and suspension Vero cells(ウイルスワクチン生産のためのプラットホーム技術:付着および懸濁ベロ細胞間の比較)。Poster and Abstract P70. In: 21st Meeting of the European Society for Animal Cell Technology, Programme and Book of Abstracts。
(7)
Fallaux(ファラーオクス)FJ、Bout(バウト)A、van der Velde(ファン・デア・フェルデ)I、van den Wollenberg(ファン・デン・ウォレンベルグ)DJ、Hehir(ヘイア)KM、Keegan(キーガン)Jら。New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses(ニューヘルパー細胞およびマッチド初期領域1欠失アデノウイルスベクターは複製可能なアデノウイルスの生成を防止する)。Hum Gene Ther 1998 Sep 1;9(13):1909-17。
(8)
Furey(フーレー)J。Scale-up of a cell culture perfusion process-A low-shear filtration system that inhibits filter-membrane fouling(細胞培養かん流プロセスでのスケールアップ−フィルタ-膜付着物を抑制する低せん断ろ過システム)。Genetic Engineering News. Vol. 22, No. 7, April 2002。
(9)
Jiang(チャン)S、Pye(パイ)D、Cox(コックス)JC。1986年。Inactivation of poliovirus with β-propiolactone(β-プロピオラクトンによるポリオウイルスの不活化)。J. Biol. Stand. 14: 103-109。
(10)
John(ジョン)J。2009年。Role of injectable and oral polio vaccines in polio eradication(ポリオ根絶での注射可能で経口性ポリオワクチンの役割)。Expert Rev. Vaccines 8: 5-8。
(11)
Kew(ケウ)OM、Sutter(スーター)RW、de Gourville(デ・グールヴィレ)EM、Dowdle(ダウドル)WR、Pallansch(パランシュ)MA。2005年。Vaccine-derived polioviruses and the endgame strategy for global polio eradication(ワクチン由来ポリオウイルスおよび世界的なポリオ根絶のための終盤戦略)。Annu. Rev. Microbiol. 59: 587-635。
(12)
Kral(クラール)KM、Golden(ゴールデン)K、Zijlstra(ザイルストラ)G、Swaving(スワビング)J、Nieboer(ニーボア)M、Chon(チョン)JH。2009年。Advances in high yielding platform production processes using the PER.C6(R) human cell line(PER.C6(R)ヒト細胞系を使用する高収率プラットホーム生産プロセスの進歩)。Abstract P142. In: 21st Meeting of the European Society for Animal Cell Technology, Programme and Book of Abstracts。
(13)
Merten(メルテン)O.-W.、Wu(ウー)R、Couve(クーブ)E、Crainic(クライニク)R。1997年。Evaluation of the serum-free medium MDSS2 for the production of poliovirus on Vero cells in bioreactors(バイオリアクターにおけるベロ細胞のポリオウイルスの生産のための無血清培地MDSS2の評価)。Cytotechnology 25: 35-44。
(14)
Montagnon(モンタグノン)B、Vincent-Falquet(ヴィンセント-ファルクェ)JC、Fanget(ファンゲ)B。1982年。Thousand litre scale microcarrier culture of Vero cells for killed poliovirus vaccine(死滅されたポリオウイルスワクチンのためのベロ細胞の千リットルスケールのマイクロキャリヤー培養)。Promising results. Develop. Biol. Standard. 55: 37-42。
(15)
Montagnon BJ、Fanget B、Vincent-Falquet JC。1984年。Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier(マイクロキャリヤー上でのベロ細胞の培養によって調製された不活性化ポリオウイルスワクチンの産業規模生産)。Rev. Infect. Dis. 6 (suppl. 2): S341-S344。
(16)
Pau(ポー)MG、Ophorst(オフエルスト)C、Koldijk(コリダイク)MH、Schouten(スハウテン)G、Mehtali(メータリ)M、Uytdehaag(オイテハーグ)F。The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines(ヒト細胞系PER.C6はインフルエンザワクチンの生産のために新しい製造システムに提供する)。Vaccine 2001 Mar 21;19(17-19):2716-21。
(17)
Van Wezel(ヴァン・ウェツェル)AL、van Steenis(スティーニース)G、Hannik(ハンニク)CA、Cohen(コーエン)H。1978年。New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines(濃縮して精製された不活性化ポリオおよび狂犬病組織培養ワクチンの生産への新しいアプローチ)。Develop. biol. Standard. 41: 159-168。
(18)
Wright(ライト)PF、Modlin(モドリン)JF。2008年。The demise and rebirth of Polio-A modern Phoenix?(ポリオの消滅および再生−現代のフェニックス?)。J. Infect. Dis. 197: 335-336。
(19)
Yakovenko(ヤコベンコ)ML、Korotkova(コロトコフ)EA、Ivanova(イワノーワ)OE、Eremeeva(エレメバ)TPら。2009年。Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance(抗原特性の明らかな変化のない病原性派生物へのセービンワクチンの進化:目下のポリオウイルス監視を改善する必要性)。J. Virol. 83: 3402-3406。
(20)
Yallop(ヤロップ)C、Crowley(クローリー)J、Cote(コート)J、Hegmans-Brouwer(ヘーグマンズ-ブラウエル)K、Lagerwerf(ラガーウェルフ)F、Gagne(ガニエ)R、Martin(マーティン)JC、Oosterhuis(オーステルハイス)N、Opstelten(オプステルテン)DJ、Bout(バウト)A。Per.C6 cells for the manufacture of biopharmaceutical proteins(生物薬剤タンパク質の製造のためのPer.C6細胞)。Modern Biopharmaceuticals-Design, Development and Optimization. Vol. 3, 2005。
Claims (11)
- 次のステップ
a)ECACC第96022940号の下で受託されたPER.C6細胞で表される細胞の無血清懸濁培養物を提供すること、
b)前記細胞をポリオウイルスにより、5×10 6 細胞/mlおよび50×10 6 細胞/mlの間の細胞密度で感染させること、および
c)ポリオウイルスを感染後12および48時間の間の時間で収集すること
を含む、ポリオウイルスの生産のための方法。 - 前記感染および/またはウイルス増殖を34℃および36℃の間の温度で実行する、請求項1に記載の方法。
- 前記感染を5×106細胞/mlおよび20×106細胞/mlの間の細胞密度で実行する、請求項1または2に記載の方法。
- 前記感染を10×106 ±10%細胞/mlの細胞密度で実行する、請求項1ないし3のいずれか一項に記載の方法。
- 前記感染を1および3の間の感染多重度(MOI)で実行する、請求項1ないし4のいずれか一項に記載の方法。
- 前記ポリオウイルスの収集を感染後18および30時間の間の時間で実行する、請求項1ないし5のいずれか一項に記載の方法。
- 前記ポリオウイルスは、ポリオウイルス型1、ポリオウイルス型2またはポリオウイルス型3である、請求項1ないし6のいずれか一項に記載の方法。
- 前記ポリオウイルスは、ポリオウイルス型1株マホーニー、ポリオウイルス型2株MEF、またはポリオウイルス型3株ソーケットである、請求項7に記載の方法。
- 前記ポリオウイルスは弱毒性ポリオウイルスである、請求項7に記載の方法。
- 弱毒性ポリオウイルスはセービン株である、請求項9に記載の方法。
- 請求項1ないし10のいずれか一項に記載の方法を含み、さらにポリオワクチンを得るために収集したポリオウイルスを精製すること、随意に不活化すること、および調剤することを含む、ポリオワクチンを生産するための方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27103809P | 2009-07-16 | 2009-07-16 | |
US61/271,038 | 2009-07-16 | ||
EP09165620 | 2009-07-16 | ||
EP09165620.7 | 2009-07-16 | ||
PCT/EP2010/059796 WO2011006823A1 (en) | 2009-07-16 | 2010-07-08 | Production of polio virus at high titers for vaccine production |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012532616A JP2012532616A (ja) | 2012-12-20 |
JP5845178B2 true JP5845178B2 (ja) | 2016-01-20 |
Family
ID=41412431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012519981A Active JP5845178B2 (ja) | 2009-07-16 | 2010-07-08 | ワクチン生産のためのポリオウイルスの高力価での生産 |
Country Status (33)
Country | Link |
---|---|
US (4) | US8546123B2 (ja) |
EP (1) | EP2454364B1 (ja) |
JP (1) | JP5845178B2 (ja) |
KR (1) | KR101548790B1 (ja) |
CN (1) | CN102482647B (ja) |
AP (1) | AP3140A (ja) |
AR (1) | AR077314A1 (ja) |
AU (1) | AU2010272685B2 (ja) |
BR (1) | BR112012000942B8 (ja) |
CA (1) | CA2763091C (ja) |
CO (1) | CO6491042A2 (ja) |
CU (1) | CU20120006A7 (ja) |
DK (1) | DK2454364T3 (ja) |
EA (1) | EA020563B1 (ja) |
ES (1) | ES2484093T3 (ja) |
HK (1) | HK1164922A1 (ja) |
HR (1) | HRP20140597T1 (ja) |
IL (1) | IL217465A (ja) |
MA (1) | MA33429B1 (ja) |
MX (1) | MX2011012648A (ja) |
MY (1) | MY183385A (ja) |
NZ (1) | NZ596880A (ja) |
PE (1) | PE20120571A1 (ja) |
PL (1) | PL2454364T3 (ja) |
PT (1) | PT2454364E (ja) |
RS (1) | RS53377B (ja) |
SG (1) | SG177655A1 (ja) |
SI (1) | SI2454364T1 (ja) |
SM (1) | SMT201400079B (ja) |
TN (1) | TN2011000628A1 (ja) |
TW (1) | TWI477606B (ja) |
WO (1) | WO2011006823A1 (ja) |
ZA (1) | ZA201108271B (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9254318B2 (en) | 2006-03-31 | 2016-02-09 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
KR101504392B1 (ko) | 2008-11-03 | 2015-03-19 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터의 제조방법 |
NZ596880A (en) * | 2009-07-16 | 2013-10-25 | Crucell Holland Bv | Production of polio virus at high titers for vaccine production |
US9109013B2 (en) | 2009-10-26 | 2015-08-18 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
BR112015018493A2 (pt) * | 2013-02-05 | 2017-08-22 | Univ Georgia | Linhagens celulares para produção de vírus e métodos de uso |
KR102236498B1 (ko) | 2013-03-08 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 무세포 백일해 백신 |
CN105121634B (zh) | 2013-03-13 | 2019-07-26 | 易木农麦克斯有限公司 | 具有提高的病毒生产能力的细胞系及其生产方法 |
KR20140112255A (ko) | 2013-03-13 | 2014-09-23 | 고려대학교 산학협력단 | 바이러스 생산능이 증가된 세포주 및 그 제조방법 |
GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
SI3010537T1 (sl) | 2013-06-17 | 2018-09-28 | De Staat der Nederlanden, Vert. Door de Minister Van Vws Ministerie Van Volksgezondheid Welzijn en Sport | Metode za preprečevanje agregacije virusnih komponent |
JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
US20160053281A1 (en) * | 2013-08-15 | 2016-02-25 | The University Court Of The University Of Edinburgh | Enhanced Expression Of RNA Vectors |
WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
WO2015193324A1 (en) | 2014-06-17 | 2015-12-23 | Crucell Holland B.V. | Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains |
US10526393B2 (en) | 2014-06-18 | 2020-01-07 | Immunomax Co., Ltd. | Method for promoting virus infection and increasing virus production, by using cell line having lost BST2 gene functions |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
BR112017001177B1 (pt) * | 2014-07-24 | 2022-05-24 | Janssen Vaccines & Prevention B.V | Método de purificação e de potenciação da liberação de poliovírus a partir de uma colheita de cultura celular bruta contendo poliovírus e uso de um detergente catiônico |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US10372100B2 (en) * | 2016-08-29 | 2019-08-06 | Ge Healthcare Bio-Sciences Corp. | Manufacturing system for biopharmaceutical products |
US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
CN107723279B (zh) * | 2017-10-18 | 2020-11-10 | 成都远睿生物技术有限公司 | 一种缺陷型腺病毒AdC68-GP的培养方法 |
EP3749757A4 (en) | 2018-02-07 | 2021-11-24 | Bharat Biotech International Limited | PROCEDURES FOR ENTEROVIRUS CLEANING AND INACTIVATION AND VACCINE COMPOSITIONS RESULTED FROM THEM |
JP2022527235A (ja) | 2019-01-23 | 2022-06-01 | 義裕 河岡 | インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異 |
CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
US20220175908A1 (en) | 2019-05-16 | 2022-06-09 | Janssen Vaccines & Prevention B.V. | Methods for Inducing a Safe Immune Response Against Polio Virus |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525349A (en) * | 1981-12-29 | 1985-06-25 | Societe Anonyme Dite: Institut Merueux | Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
EP1256803A1 (en) * | 2001-05-07 | 2002-11-13 | Crucell Holland B.V. | Methods for the identification of antiviral compounds |
EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
EP1573012B1 (en) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
CN101328473B (zh) | 2003-05-09 | 2012-05-02 | 克鲁塞尔荷兰公司 | E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法 |
EP2540815A1 (en) | 2004-03-05 | 2013-01-02 | DSM IP Assets B.V. | Perfusion cell culture |
EP1793852A1 (en) | 2004-08-27 | 2007-06-13 | Panacea Biotec Ltd. | Inactivated poliomyelitis vaccine derived from sabin strain of polio virus |
PT1802336E (pt) | 2004-10-14 | 2011-11-15 | Glaxosmithkline Biolog Sa | Vacinas de dose inicial/reforço para a malária |
CN100500827C (zh) * | 2004-11-26 | 2009-06-17 | 中国医学科学院医学生物学研究所 | 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法 |
EP2081589B1 (en) | 2006-11-16 | 2010-10-06 | Crucell Holland B.V. | Complementation of factor xi deficiency by factor v mutants |
NZ596880A (en) | 2009-07-16 | 2013-10-25 | Crucell Holland Bv | Production of polio virus at high titers for vaccine production |
KR20120070015A (ko) | 2010-12-21 | 2012-06-29 | (주)창조바이오텍 | 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물 |
-
2010
- 2010-07-08 NZ NZ596880A patent/NZ596880A/xx not_active IP Right Cessation
- 2010-07-08 KR KR1020127001501A patent/KR101548790B1/ko active IP Right Grant
- 2010-07-08 SG SG2012002705A patent/SG177655A1/en unknown
- 2010-07-08 MX MX2011012648A patent/MX2011012648A/es active IP Right Grant
- 2010-07-08 AU AU2010272685A patent/AU2010272685B2/en not_active Ceased
- 2010-07-08 MA MA34534A patent/MA33429B1/fr unknown
- 2010-07-08 BR BR112012000942A patent/BR112012000942B8/pt not_active IP Right Cessation
- 2010-07-08 PT PT107298952T patent/PT2454364E/pt unknown
- 2010-07-08 DK DK10729895.2T patent/DK2454364T3/da active
- 2010-07-08 PL PL10729895T patent/PL2454364T3/pl unknown
- 2010-07-08 CA CA2763091A patent/CA2763091C/en active Active
- 2010-07-08 MY MYPI2012000173A patent/MY183385A/en unknown
- 2010-07-08 EA EA201270173A patent/EA020563B1/ru not_active IP Right Cessation
- 2010-07-08 RS RS20140325A patent/RS53377B/en unknown
- 2010-07-08 JP JP2012519981A patent/JP5845178B2/ja active Active
- 2010-07-08 WO PCT/EP2010/059796 patent/WO2011006823A1/en active Application Filing
- 2010-07-08 CN CN201080026814.2A patent/CN102482647B/zh active Active
- 2010-07-08 SI SI201030661T patent/SI2454364T1/sl unknown
- 2010-07-08 AP AP2012006075A patent/AP3140A/xx active
- 2010-07-08 EP EP10729895.2A patent/EP2454364B1/en active Active
- 2010-07-08 PE PE2012000051A patent/PE20120571A1/es active IP Right Grant
- 2010-07-08 ES ES10729895.2T patent/ES2484093T3/es active Active
- 2010-07-14 AR ARP100102556A patent/AR077314A1/es active IP Right Grant
- 2010-07-15 TW TW099123327A patent/TWI477606B/zh not_active IP Right Cessation
- 2010-07-16 US US12/804,242 patent/US8546123B2/en active Active
-
2011
- 2011-11-10 ZA ZA2011/08271A patent/ZA201108271B/en unknown
- 2011-12-07 TN TNP2011000628A patent/TN2011000628A1/en unknown
-
2012
- 2012-01-10 IL IL217465A patent/IL217465A/en active IP Right Grant
- 2012-01-13 CU CU2012000006A patent/CU20120006A7/es unknown
- 2012-01-16 CO CO12005515A patent/CO6491042A2/es unknown
- 2012-05-31 HK HK12105337.7A patent/HK1164922A1/xx not_active IP Right Cessation
- 2012-10-25 US US13/660,412 patent/US20130052224A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/843,052 patent/US20130273106A1/en not_active Abandoned
-
2014
- 2014-05-12 US US14/275,392 patent/US9022240B2/en active Active
- 2014-06-24 SM SM201400079T patent/SMT201400079B/xx unknown
- 2014-06-26 HR HRP20140597AT patent/HRP20140597T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5845178B2 (ja) | ワクチン生産のためのポリオウイルスの高力価での生産 | |
ES2488818T3 (es) | Método para la producción a gran escala de virus | |
AU2002338667B2 (en) | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture | |
Sanders et al. | PER. C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine | |
CA2624544C (en) | Vero cell line adapted to grow in suspension | |
DK3010537T3 (en) | PROCEDURE FOR PREVENTING AGGREGATION OF VIRUS COMPONENTS | |
Liu et al. | Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture | |
KR20010072556A (ko) | 바이러스의 증식 및 생육을 위한 배지 및 이를 위한 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5845178 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |